Checkpoint Therapeutics, Inc.

CKPT

Explore Our Financial Data > Companies > Checkpoint Therapeutics, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	CKPT
CIK	0001651407
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	95 SAWYER ROAD, SUITE 110, WALTHAM, MA, 02453
Website	checkpointtx.com
Phone	781-652-4500
CEO	James F. Oliviero
Employees	10

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$41,000.00
Pre-Tax Income	$-56.51 million
Net Income	$-56.51 million
Net Income to Common	$-56.51 million
EPS	$-0.94

View All

Balance Sheet

Cash	$33.04 million
Assets	$34.16 million
Liabilities	$17.87 million
Common Equity	$16.30 million
Liabilities & Equity	$34.16 million

View All

Cash Flow Statement

Net Income	$-56.51 million
Cash From Operating Activities	$-36.31 million
Cash From Investing Activities	N/A
Cash From Financing Activities	$58.11 million
Change in Cash	$21.80 million

View All

Calculations

NOPAT	$-39.46 million
EBITDA	$-56.52 million
Price to Earnings	N/A
Price to Book	$22.75
ROE	-1869.55%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Emrosi™ commercial launch initiated for the treatment of inflammatory lesions of rosacea in adults Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; special meeting of Checkpoint stockholders to approve the transaction to take place on May 28, 2025 FDA accepted New Drug Application filing for priority review of CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, May 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”),

Article Link

Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates

UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA in December 2024 as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma Special meeting of stockholders to vote on Merger to take place on May 28, 2025 WALTHAM, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2025, and recent corp

Article Link

High Growth Tech Stocks in the US for April 2025

Over the last 7 days, the United States market has dropped 5.6%, yet it remains up by 3.3% over the past year, with earnings projected to grow by 14% annually in the coming years. In this context, identifying high growth tech stocks involves focusing on companies that can capitalize on robust earnings potential and demonstrate resilience amid recent market fluctuations.

Article Link

3 Growth Companies Insiders Are Betting On

In the wake of recent market turbulence sparked by new tariffs, U.S. indices have experienced significant declines, highlighting the volatility and uncertainty that currently characterize the investment landscape. Amidst this backdrop, companies with high insider ownership can offer a unique perspective on potential growth opportunities, as insiders often have a deep understanding of their company's prospects and may be more inclined to invest in times of market stress.

Article Link

Checkpoint Therapeutics Full Year 2024 Earnings: US$1.42 loss per share (vs US$1.87 loss in FY 2023)

Checkpoint Therapeutics ( NASDAQ:CKPT ) Full Year 2024 Results Key Financial Results Net loss: US$56.2m (loss widened...

Article Link